Shukra Medtech financing covered working capital and capex
Key highlights
- Shukra Medtech generated Rs 43.31 lakh of operating cash in the half year ended September 30, 2026.
- Trade receivables, inventories and other assets used a combined Rs 39.41 crore of cash in the half year ended September 30, 2026.
- Net financing inflows were Rs 19.94 crore, including Rs 17.48 crore of net borrowing proceeds.
- Total borrowings rose to Rs 22.50 crore at September 30, 2026 from Rs 5.02 crore at March 31, 2026.
powered by IRIS

Shukra Medtech Limited generated Rs 43.31 lakh of operating cash in the half year ended September 30, 2026, while Rs 19.94 crore of net financing inflows supported working-capital growth and Rs 15.33 crore of net investing outflows. Higher receivables, inventories and other assets absorbed most of the Rs 38.54 crore operating profit before working-capital changes.
Know Shukra Medtech inside out
Results, valuation, peers and who's buying, in one view.
How much operating cash did Shukra Medtech generate?
Shukra Medtech generated Rs 43.31 lakh in net cash from operating activities in the half year ended September 30, 2026, down from Rs 3.02 crore in the corresponding half year ended September 30, 2025. The cash-flow statement uses the indirect method under Indian Accounting Standard 7, starting with profit before tax and adjusting for non-cash and financing-related items.
Profit before tax rose to Rs 36.00 crore from Rs 1.57 crore a year earlier. Adding Rs 2.20 crore of depreciation and amortisation and Rs 57.03 lakh of interest expense, while deducting Rs 23.39 lakh of interest income, produced operating profit before working-capital changes of Rs 38.54 crore, compared with Rs 2.95 crore in the prior-year period.
That operating profit was substantially absorbed by a net Rs 38.10 crore working-capital outflow. Cash generated from operations was therefore Rs 43.31 lakh before taxes, with no direct-tax payment or refund reported in either half-year cash-flow column. The gap between reported profit before tax and operating cash reflects cash tied up in operating assets during the period.
What working-capital items used Shukra Medtech's cash?
Shukra Medtech used Rs 15.76 crore for higher trade receivables, Rs 9.51 crore for inventories and Rs 14.14 crore for other assets during the half year ended September 30, 2026. These three increases together used Rs 39.41 crore, partly offset by a Rs 2.79 crore increase in trade payables.
Other liabilities declined by Rs 1.48 crore, creating an additional cash use. In the prior-year half year, inventories used Rs 5.94 crore, trade payables fell by Rs 94.16 lakh and other assets released Rs 1.67 crore. The 2026 period therefore included a larger inventory build and a change in other assets from a cash release to a cash use.
The balance sheet records the same direction of movement between March 31, 2026 and September 30, 2026. Trade receivables increased to Rs 38.71 crore from Rs 22.95 crore, inventories rose to Rs 23.42 crore from Rs 13.90 crore, and other current assets rose to Rs 53.10 crore from Rs 38.75 crore. Trade payables increased to Rs 12.86 crore from Rs 10.07 crore.
How much did Shukra Medtech invest in assets?
Shukra Medtech reported Rs 15.33 crore of net cash used in investing activities for the half year ended September 30, 2026, compared with Rs 41.39 lakh used a year earlier. The investing section lists purchases of property, plant and equipment, including capital work-in-progress, capital advances and capital creditors, alongside Rs 23.39 lakh of interest received.
Capital work-in-progress increased to Rs 26.09 crore at September 30, 2026 from Rs 11.91 crore at March 31, 2026. Property, plant and equipment declined to Rs 20.91 crore from Rs 21.72 crore over the same dates, while total non-current assets rose to Rs 46.99 crore from Rs 33.63 crore because of the increase in work-in-progress.
The disclosed cash-flow presentation means the Rs 15.33 crore net investing outflow includes the effect of interest received. The balance-sheet movement shows that the investment was weighted toward projects still classified as capital work-in-progress rather than completed property, plant and equipment at September 30, 2026.
Got a follow-up? Ask IRIS
How did Shukra Medtech fund the cash requirement?
Shukra Medtech generated Rs 19.94 crore of net cash from financing activities in the half year ended September 30, 2026, reversing a Rs 1.36 crore net financing outflow in the prior-year half year. The principal inflows were Rs 17.48 crore of net borrowing proceeds and Rs 7.76 crore from issue of share capital.
Financing outflows included Rs 4.72 crore under money received against share warrants and Rs 57.03 lakh of interest paid. No dividend payment was recorded in the 2026 half year, whereas the prior-year period showed Rs 43.79 lakh of dividends paid. Shukra Medtech also said convertible warrants issued preferentially in an earlier period were converted into equity shares during the 2026 half year.
Total borrowings rose to Rs 22.50 crore at September 30, 2026 from Rs 5.02 crore at March 31, 2026. Non-current borrowings were Rs 9.63 crore and current borrowings were Rs 12.87 crore, compared with Rs 3.19 crore and Rs 1.83 crore respectively at March 31. Cash and cash equivalents increased to Rs 11.02 crore from Rs 5.98 crore after the Rs 5.05 crore net increase in cash during the period.
What does the funding pattern show for Shukra Medtech?
Shukra Medtech's reported Rs 25.67 crore net profit for the half year did not translate into comparable operating cash because receivables, inventories and other assets consumed Rs 38.10 crore. Financing inflows of Rs 19.94 crore were larger than the Rs 15.33 crore investing outflow and, together with Rs 43.31 lakh of operating cash, produced the Rs 5.05 crore increase in cash balances.
The consolidated results show two operating segments: Shukra Pharmaceutical and Shukra MedTech. The Shukra MedTech segment reported Rs 12.51 crore of revenue and Rs 3.10 crore of profit before tax and interest in the half year ended September 30, 2026, while the Shukra Pharmaceutical segment reported Rs 56.33 crore of revenue. The cash-flow statement does not allocate working-capital use, capital expenditure or borrowings between those segments.
Conclusion
The September 2026 half-year disclosures show that Shukra Medtech paired higher borrowing and share-capital proceeds with investment spending and a substantial build-up in operating assets. Profit before tax increased to Rs 36.00 crore, but cash from operations was Rs 43.31 lakh as receivables, inventories and other assets rose, while investing activities used Rs 15.33 crore.
The next reported period should show whether the Rs 38.10 crore working-capital outflow converts into customer collections and whether the Rs 26.09 crore of capital work-in-progress is completed or rises further. The disclosed balance-sheet measures to watch are the Rs 22.50 crore borrowing balance, cash and cash equivalents of Rs 11.02 crore, and any further effect from converted preferential warrants.


